Get the Stockscreener App
9.83
3.26%
0.31
Oric Pharmaceuticals Inc stock is traded at $9.83, with a volume of 932.58K.
It is up +3.26% in the last 24 hours and down -11.44% over the past month.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
See More
Previous Close:
$9.52
Open:
$9.56
24h Volume:
932.58K
Relative Volume:
0.72
Market Cap:
$837.75M
Revenue:
-
Net Income/Loss:
$-119.87M
P/E Ratio:
-5.4309
EPS:
-1.81
Net Cash Flow:
$-109.90M
1W Performance:
-0.51%
1M Performance:
-11.44%
6M Performance:
+18.86%
1Y Performance:
+11.20%
1-Day Range:
$9.56
$10.31
1-Week Range:
$8.97
$10.31
52-Week Range:
$3.8951
$14.67
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
Name
Oric Pharmaceuticals Inc
Sector
Industry
Phone
(650) 388-5600
Address
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Compare ORIC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
9.83 | 811.28M | 0 | -119.87M | -109.90M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-08-25 | Initiated | Ladenburg Thalmann | Buy |
| Oct-31-24 | Initiated | Wells Fargo | Overweight |
| Sep-06-24 | Initiated | Stifel | Buy |
| Feb-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-22-23 | Initiated | Wedbush | Outperform |
| Mar-23-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-21-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-16-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-18-22 | Resumed | Oppenheimer | Perform |
| Apr-04-22 | Upgrade | Citigroup | Neutral → Buy |
| Mar-25-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-22-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-22-22 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-06-21 | Upgrade | Citigroup | Neutral → Buy |
| Jan-25-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-13-20 | Initiated | Robert W. Baird | Outperform |
| Aug-06-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| May-19-20 | Initiated | Citigroup | Neutral |
| May-19-20 | Initiated | Guggenheim | Buy |
| May-19-20 | Initiated | JP Morgan | Overweight |
| May-19-20 | Initiated | Jefferies | Buy |
View All
Oric Pharmaceuticals Inc Stock (ORIC) Latest News
Oric Pharmaceuticals Faces Potential Setbacks Amid Competitors’ Clinical Trials - TipRanks
Jefferies Reiterates Buy Rating on Oric Pharmaceuticals with $23 Price Target. - AInvest
Guggenheim Reaffirms Buy Rating for ORIC Pharmaceuticals with $18 Target Price. - AInvest
Moving Average Trends for ORIC Pharmaceuticals Inc. Stock: What They IndicateWeekly Risk Report & Free Risk Controlled Daily Trade Plans - Newser
Guggenheim Reiterates Buy Rating for ORIC Pharmaceuticals | ORIC Stock News - GuruFocus
ORIC Pharmaceuticals stock price target raised to $23 by Jefferies - Investing.com Canada
How to manage a losing position in ORIC Pharmaceuticals Inc.2025 Pullback Review & Short-Term Trading Opportunity Alerts - Newser
ORIC Pharmaceuticals Inc. stock momentum explainedEarnings Miss & High Return Trade Opportunity Guides - Newser
Oppenheimer Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $12 - 富途牛牛
Will ORIC Pharmaceuticals Inc. see short term momentum2025 Top Gainers & Fast Gain Stock Tips - Newser
Can volume confirm reversal in ORIC Pharmaceuticals Inc.Portfolio Return Summary & Precise Buy Zone Tips - Newser
Using flow based indicators on ORIC Pharmaceuticals Inc.Real-Time Investment Signal Forecast with AI - Newser
Using economic indicators to assess ORIC Pharmaceuticals Inc. potentialStrategy Playbook for Risk Controlled Trades - Newser
ORIC® Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates - GlobeNewswire
ORIC Pharmaceuticals Trims Costs To Back Key Drug Trials - Finimize
Vivo Capital LLC Buys 802,632 Shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
Oric Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
ORIC Pharmaceuticals reports Q2 net loss of $36.4 mln - MarketScreener
What makes ORIC Pharmaceuticals Inc. stock price move sharplySummary of Trade Cycles in 5-Year Range - Newser
Will a bounce in ORIC Pharmaceuticals Inc. offer an exitAI Trend Detection for Entry Timing - Newser
Market reaction to ORIC Pharmaceuticals Inc.’s recent newsAI Pattern Recognition and Trade Prediction - Newser
What data driven models say about ORIC Pharmaceuticals Inc.’s futureROI Prediction from Long-Term Holding Plans - Newser
What Fibonacci levels say about ORIC Pharmaceuticals Inc. reboundPrice Forecast Based on AI Analysis - Newser
ORIC Pharmaceuticals Inc.’s volatility index tracking explainedFree Breakout Confirmation With Entry Tracker - Newser
Volume spikes in ORIC Pharmaceuticals Inc. stock – what they meanAI Enhanced Strategy for Portfolio Growth - Newser
ORIC Pharmaceuticals Inc. Attempts Reversal From Key SupportDaily Stock Market Swing Alerts Highlight Key Movers - beatles.ru
Will ORIC Pharmaceuticals Inc. continue its uptrendReal-Time Entry Forecast with Accuracy Metrics - Newser
How to forecast ORIC Pharmaceuticals Inc. trends using time seriesPredictive System for Long-Term Stock Forecast - Newser
Is ORIC Pharmaceuticals Inc. a candidate for recovery playMonthly Long-Term Market Recap and Summary - Newser
Key resistance and support levels for ORIC Pharmaceuticals Inc.Bull Market Summary and Recovery Outlook - Newser
Is ORIC Pharmaceuticals Inc. a Top Dividend Stock to Watch in 2025In-Depth Stock Trading Volume Analysis - Newser
Using data filters to optimize entry into ORIC Pharmaceuticals Inc.Stock Market Watch with Smart Filters - Newser
Oric Pharmaceuticals (ORIC) to Release Quarterly Earnings on Monday - MarketBeat
Can ORIC Pharmaceuticals Inc. rally from current levelsFree Watchlist for Low Risk High Return - Newser
Oric Pharmaceuticals (ORIC) Projected to Post Quarterly Earnings on Monday - Defense World
ORIC Pharmaceuticals ORIC 2025Q2 Earnings Preview Upside Potential Due to Innovative Drug Development - AInvest
Oric Pharmaceuticals Inc Stock (ORIC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):